Form 4: aTyr Pharma Director Acquires 100,000 Stock Options

Director Eric Benevich of aTyr Pharma acquired 100,000 stock options on December 10, 2024, which vest over a three-year period.

Summary

• Eric Benevich, a director at aTyr Pharma, was granted 100,000 stock options on December 10, 2024.
• The options have an exercise price of $3.29 per share.
• These options will vest in 36 equal monthly installments starting January 10, 2025, and will be fully vested by December 10, 2027.
• The vesting is contingent upon Mr. Benevich's continued service on the company's Board of Directors.
• The options expire on December 10, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock option grants to directors, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the options is dependent on the future performance of aTyr Pharma's stock price.
• If the director leaves the board before the options are fully vested, they may forfeit some or all of the options.

Future Outlook

The director's stock options will vest over the next three years, contingent on continued service on the board.

Industry Context

Stock option grants are a common form of compensation for directors and executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating board members in the biotech industry.
• The vesting schedule of 36 months is typical for such grants, encouraging long-term commitment.
• The exercise price of $3.29 is a fixed price at the time of the grant, and the value of the options will fluctuate with the stock price.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it aligns the director's interests with the company's long-term performance.
• The vesting schedule encourages the director's continued service on the board.

Key Dates

Keywords

stock options, insider trading, director, equity, aTyr Pharma, ATYR, vesting